Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Deruxtecan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2
    Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2

    30 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251030008969/en/DESTINY-Lung06-Phase-3-Trial-of-ENHERTU-Initiated-as-First-Line-Therapy-in-Patients-with-HER2-Overexpressing-Metastatic-Non-Squamous-Non-Small-Cell-Lung-Cancer

    BUSINESSWIRE
    30 Oct 2025
    Share Share
    Iambic Collaborates With Jazz Pharma On Her2+ Breast Cancer Study
    Iambic Collaborates With Jazz Pharma On Her2+ Breast Cancer Study

    21 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251021091520/en/Iambic-Announces-Research-Collaboration-with-Jazz-Pharmaceuticals-for-IAM1363-and-Zanidatamab-Combination-Cohort-in-HER2-Positive-Breast-Cancer

    BUSINESSWIRE
    21 Oct 2025
    Share Share
    ESMO: Daiichi, Merck Move Ovarian Cancer ADC Toward Pivotal Test
    ESMO: Daiichi, Merck Move Ovarian Cancer ADC Toward Pivotal Test

    20 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-daiichi-merck-power-ovarian-cancer-adc-toward-pivotal-trial-after-passing-phase-2-test

    FIERCE BIOTECH
    20 Oct 2025
    Share Share
    Datroway Shows 5-Month Survival Gain Over Chemotherapy
    Datroway Shows 5-Month Survival Gain Over Chemotherapy

    19 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251019553773/en/DATROWAY-datopotamab-deruxtecan-dlnk-demonstrated-unprecedented-median-overall-survival-improvement-of-five-months-vs.-chemo-as-1st-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-for-whom-immunotherapy-was-not-an-option

    BUSINESSWIRE
    19 Oct 2025
    Share Share
    Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer
    Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer

    18 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251018027927/en/ENHERTU-fam-trastuzumab-deruxtecan-nxki-reduced-the-risk-of-disease-recurrence-or-death-by-53-vs.-T-DM1-in-patients-with-high-risk-HER2-positive-early-breast-cancer-following-neoadjuvant-therapy-in-DESTINY-Breast05-Phase-III-trial

    BUSINESSWIRE
    18 Oct 2025
    Share Share
    ENHERTU® Preceded By THP Yields 67% Pathologic Response
    ENHERTU® Preceded By THP Yields 67% Pathologic Response

    18 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251018622942/en/ENHERTU-fam-trastuzumab-deruxtecan-nxki-followed-by-THP-before-surgery-resulted-in-a-pathologic-complete-response-in-67-of-patients-with-high-risk-HER2-positive-early-stage-breast-cancer-in-DESTINY-Breast11-Phase-III-trial

    BUSINESSWIRE
    18 Oct 2025
    Share Share